GBT
JUNO

Grove Bank & Trust’s Juno Therapeutics, Inc. JUNO Stock Holding History

Grove Bank & Trust’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$22K – 346
2015
Q4 		$22K Buy
+500
New +$24.8K 0.02% 233

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Grove Bank & Trust's JUNO Position: Q1 2016 in Review

Grove Bank & Trust sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 500 shares — an estimated $22K sold.

Grove Bank & Trust first reported a position in JUNO in Q4 2015 and held it in 1 quarter. The position peaked at $22K in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Grove Bank & Trust reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Grove Bank & Trust sold 500 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $22K.
  • Grove Bank & Trust first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Grove Bank & Trust's Juno Therapeutics, Inc. position peaked at $22K in Q4 2015.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Grove Bank & Trust's 13F filing for Q1 2016, filed 11 May 2016.